NCT06926153 (TABAPSY) is a NA clinical trial of TABAPSY in Tobacco Addiction, sponsored by GCS-CCOMS.

Who is sponsoring NCT06926153?

NCT06926153 is sponsored by GCS-CCOMS.

What drugs are being tested in NCT06926153?

Interventions in NCT06926153: TABAPSY, Usual Care.

What condition does NCT06926153 study?

NCT06926153 studies Tobacco Addiction.

Is NCT06926153 still recruiting?

NCT06926153 is currently recruiting now. Last updated 2 February 2026.

Last reviewed 2026-02-02 · How we verify

NCT06926153: TABAPSY

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Interventional Study on Smoking Reduction in Psychiatry

Recruiting now NA Last updated 2 February 2026

What this trial tests

NA trial testing TABAPSY in Tobacco Addiction in 6,500 participants. Currently enrolling.

Timeline

15 January 2025

Primary endpoint
14 May 2026

14 November 2026

Quick facts

Lead sponsor	GCS-CCOMS
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	6,500
Start date	15 January 2025
Primary completion	14 May 2026
Estimated completion	14 November 2026
Sites	22 locations across Guadeloupe, France, Reunion

Drugs / interventions tested

TABAPSY
Usual Care

Conditions studied

Tobacco Addiction — all drugs for Tobacco Addiction →

Sponsor

GCS-CCOMS

Who can join

18 and older, any sex, with Tobacco Addiction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The smoking rate among people with mental disorders is higher than in the general population. Greater exposure to the harmful effects of tobacco partly explains the major inequality in life expectancy observed among people with mental disorders who, depending on the disorder and the study, live 10 to 25 years less than the general population, a gap mainly due to the occurrence of cardiovascular and respiratory pathologies, notably bronchial cancers. However, tobacco reduction actions specifically targeting these people remain insufficiently developed, particularly in psychiatry where this addiction is often banalized and its treatment neglected. The objective of this study is to evaluate an intervention ('Tabapsy') co-constructed with mental health services users, mental health professionals, and general practitioners and targeting adult patients followed in ambulatory psychiatry. The main objective is to evaluate the effectiveness of the intervention on short-term smoking cessation (cessation for at least 7 days) among regular smokers at 3 months. Secondary objectives include evaluation of its cost-effectiveness and implementation. To this end, a national cluster-randomized controlled study will be carried out, supplemented by qualitative interviews to study the implementation of the intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06926153 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by GCS-CCOMS
Last refreshed: 2 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing